CEO's Greeting
Apimeds, Inc. will contribute to the improvement of human health and quality of life, and will lead the future strategic industry, the life science industry.
We sincerely thank our shareholders and customers for loving Apimeds.
We devoted ourselves to pain medicine using bee venom therapy for the past 20 years, and we obtained approval for a new drug for clinical research by the US FDA in 1989, and since then, in May 2003, 14 years after starting from 1990 in Korea, it has been approved for the first time (6th new drug in Korea). Currently, we are preparing for clinical trials by receiving MS (Multiple Sclerosis) Phase 3 IND from the US FDA.
Apimeds, Inc. will always be ahead of the times by actively responding to the rapidly changing era and market environment through continuous change and reform, focusing all its capabilities on new drug development and biomedical fields.
Since its establishment in September 2003, Apimeds, Inc., in order to contribute to the improvement of human health and quality of life, and to lead the life science industry, the future strategic industry of Korea, aims to achieve “a world-class new drug development company specialising in life science.” Armed with trust and professional spirit, Apimeds will do its best to become a global company loved and trusted by customers and shareholders by creating a “strong company full of the best quality and vitality.”
Thank you.
We devoted ourselves to pain medicine using bee venom therapy for the past 20 years, and we obtained approval for a new drug for clinical research by the US FDA in 1989, and since then, in May 2003, 14 years after starting from 1990 in Korea, it has been approved for the first time (6th new drug in Korea). Currently, we are preparing for clinical trials by receiving MS (Multiple Sclerosis) Phase 3 IND from the US FDA.
Apimeds, Inc. will always be ahead of the times by actively responding to the rapidly changing era and market environment through continuous change and reform, focusing all its capabilities on new drug development and biomedical fields.
Since its establishment in September 2003, Apimeds, Inc., in order to contribute to the improvement of human health and quality of life, and to lead the life science industry, the future strategic industry of Korea, aims to achieve “a world-class new drug development company specialising in life science.” Armed with trust and professional spirit, Apimeds will do its best to become a global company loved and trusted by customers and shareholders by creating a “strong company full of the best quality and vitality.”
Thank you.
CEO
Yoo Insoo, Koo Jakap
